Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1212-1216

  Piscitelli, Stephen C ^a   Vogel, Susan ^a   Figg, William D ^a   Raje, Sangeeta ^a   Forrest, Alan ^a   Metcalf, Julia A ^a   Baseler, Michael ^a   Falloon, Judith ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; CYTOKINE; GAMMA INTERFERON; INDINAVIR; INTERLEUKIN 2; INTERLEUKIN 6; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SCREENING; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; STATISTICAL ANALYSIS; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED;

EID: 0031726789     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gourevitch MN. The epidemiology of HIV and AIDS: current trends. Med Clin North Am 1996;80:1223-38.
2. Piscitelli SC, Minor JR, Saville MW, Davey RT Jr. Immune based therapies for treatment of HIV infection. Ann Pharmacother 1996;30:62-76.
3. Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a g-interferon-dependent mechanism. J Immunol 1985;134:1503-7.
4. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer-and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J Clin Invest 1985;72:398-403.
5. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
6. Davey RT Jr, Wells MJ, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in HIV-1 infected individuals. J Infect Dis 1997;175:781-9.
7. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV disease. Biotherapy 1990;2:119-36.
8. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
9. Reiss WG, Piscitelli SC. Drug-cytokine interactions: mechanisms and clinical implications. BioDrugs 1998;9:389-95.
10. D'Argenio DZ, Schumitzky A. ADAPT II user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1990.
11. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
12. Renton KW, Mannering GJ. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun 1976;73:343-8.
13. Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 1990;68:777-81.
14. Williams JF, Bement WJ, Sinclair JF, et al. Effect of interleukin-6 on pentobarbital induction of cytochrome P-450 in cultured rat hepatocytes. Biochem Biophys Res Commun 1991;178:1049-55.
15. Barker CW, Fagan JB, Pasco DS. Interleukin-1b suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J Biol Chem 1992;267:8050-5.
16. Ghezzi P, Saccardo B, Bianchi M. Induction of xanthine oxidase and heme oxygenase and depression of liver drug metabolism by interferon: a study with different recombinant interferons. J Interferon Res 1986;6:251-6.
17. Mannering GJ, Deloria LB, Abbott V. Role of xanthine oxidasein the interferon-mediated depression of the hepatic cytochrome P-450 system in mice. Cancer Res 1988;48:2107-12.
18. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines downregulate expression of major cytochrome P-450 enzymes in adult hepatocytes in primary culture. Mol Pharmacol 1993;44:707-15.
19. Fukuda Y, Ishida N, Noguchi T, et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P-450 IA1, IA2, IIIA in human hepatoma cells. Biochem Biophys Res Commun 1992;184:960-5.
20. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-75.